Table 1.

Patient characteristics

Pt #	Dose Level	Age	Sex	Race	ECOG PS	Disease	Karyotype	Prior Rx (n)	Disease Status	First Remission (mos)
1	1	75	M	White	1	MDS→2°AML	47, XY, +15	3	2nd relapse	7
2	1	69	M	White	2	MDS→2°AML	46, XY, t(3;21), del(7q)	1	primary refractory	n/a
3	1	68	M	White	0	MDS→2°AML	47, XY, +8	2	refractory relapse	7
4	1	85	F	White	0	MPN→2°AML	46, XX	1	primary refractory	n/a
5	1	20	M	American Indian	0	de novo AML	46, XY, t(8;21), del(9p)	4	refractory relapse	4.5
6	1	74	F	White	1	t-AML	46, XX,add(4q35), inv(16)	6	refractory relapse	9
7	2	74	M	White	1	RAEB/IPSS int-2	46, XY	1	primary refractory	n/a
8	2	76	M	White	1	MDS→2°AML	46, XY, del(9q13)	2	primary refractory	n/a
9	2	61	M	Black	1	MDS→2°AML	46, XY	3	refractory relapse	5
10	2	67	M	White	0	t-AML	46, XY, t(9;11), del(11q23)	1	1st relapse	6
11	3	68	F	White	0	de novo AML	45, XX, −7	4 (allo)	refractory relapse	5
12	3	76	M	Native Hawaiian	1	MDS→2°AML	47, XY, del(7q22), del(12p), +13, i(17q10)	3	primary refractory	n/a
13	3	38	M	White, Hispanic	2	Pre-B ALL	46, XY	4	refractory relapse	15